Donate
Email Password
Not a member? Sign Up   Forgot password?
Business and Economics Education Environment Health Care California
Home
About PRI
My PRI
Contact
Search
Policy Research Areas
Events
Publications
Press Room
PRI Blog
Jobs Internships
Scholars
Staff
Book Store
Policy Cast
Upcoming Events
There are no upcoming events at this time
Recent Events
Obama's Education Takeover
2.8.2012 6:00:00 PM

Lance T. Izumi, Koret Senior Fellow and PRI's Senior ... More

Health Care Reform: A Different Path - Current Federal Plan May Be Bad For Your Health
2.2.2012 11:30:00 AM
The Orange County Forum presents a luncheon and reception with ... More

Cocktail Reception—Celebrate the Book Release of The Pipes Plan: The Top Ten Ways to Dismantle and Replace ObamaCare
1.26.2012 5:30:00 PM

Celebrate the Release of Sally C. Pipes’ New Book ... More

Opinion Journal Federation
Town Hall silver partner
Lawsuit abuse victims project
Scholar
E-mail Print John R. Graham
Director, Health Care Studies and Executive Director, Benjamin Rush Society


Email

A financial analyst who researches the effects of laws and regulations on investments in the health sector, John R. Graham has been Director of Health Care Studies at the Pacific Research Institute since May 2005.  He was promoted to the additional responsibility of Executive Director of the Benjamin Rush Society in August 2011.  Other appointments include Senior Fellow of the National Center for Policy Analysis, Adjunct Scholar of the Mackinac Center for Public Policy, and member of the Board of Visitors of the Benjamin Rush Society of medical students and physicians.

Graham received his M.B.A. from the London Business School (England) and his B.A. (with Honors) in economics and commerce from the Royal Military College of Canada.  He is a Chartered Alternative Investment Analyst (CAIA Charterholder) and is an affiliate member of the CFA Society of San Francisco, having completed all three levels of the Chartered Financial Analyst (CFA) program.

His research agenda includes:

  • The effect of the 2010 federal health-reform law on returns to publicly listed firms in the health sector;
  • Quality of health plans' earnings generated by different lines of business, e.g. commercial groups, Medicaid managed-care, and Medicare Advantage;
  • Valuation of health plans' expansions into international markets;
  • The effect of regulations sponsored by the Food and Drug Administration and the European Medicines Authority on investments by venture capital and private equity in pharmaceutical and medical-device enterprises;
  • Effect of philanthropic investment in medical research on returns to commercial investment;
  • Identifying and measuring factors (alternative betas) derived from government action that explain returns to firms in the health sector; and
  • Expected contribution of investments in the health sector to traditional (long-only) and alternative portfolios under different legislative and regulatory scenarios.

He writes the monthly Health Policy Prescriptions series of analytical essays, and contributes to PRI's Capital Ideas columns on public policy.  He has written for periodicals including the Wall Street Journal and the Washington Post, and writes almost daily for a number of blogs, which are aggregated at Free American Health Care.  Readers can follow him on Twitter and Facebook.


Related Link
Related Publication
Browse by
Recent Publications
Powered by eResources